These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27911103)

  • 1. Tools for outcome prediction in patients with community acquired pneumonia.
    Khan F; Owens MB; Restrepo M; Povoa P; Martin-Loeches I
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):201-211. PubMed ID: 27911103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
    Ugajin M; Yamaki K; Hirasawa N; Yagi T
    Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of prognosis by markers in community-acquired pneumonia.
    Viasus D; Simonetti A; Garcia-Vidal C; Carratalà J
    Expert Rev Anti Infect Ther; 2013 Sep; 11(9):917-29. PubMed ID: 24053273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and significance of various scores for pneumonia severity in the management of patients with community-acquired pneumonia in China.
    Yang Y; Xu F; Shi LY; Diao R; Cheng YS; Chen XY; Jing JY; Wang XD; Shen HH
    Chin Med J (Engl); 2012 Feb; 125(4):639-45. PubMed ID: 22490488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality prediction in community-acquired pneumonia requiring mechanical ventilation; values of pneumonia and intensive care unit severity scores.
    Aydoğdu M; Ozyilmaz E; Aksoy H; Gürsel G; Ekim N
    Tuberk Toraks; 2010; 58(1):25-34. PubMed ID: 20517726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of procalcitonin level in community-acquired pneumonia in the ED.
    Park JH; Wee JH; Choi SP; Oh SH
    Am J Emerg Med; 2012 Sep; 30(7):1248-54. PubMed ID: 22030193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.
    Kasamatsu Y; Yamaguchi T; Kawaguchi T; Tanaka N; Oka H; Nakamura T; Yamagami K; Yoshioka K; Imanishi M
    Respirology; 2012 Feb; 17(2):330-6. PubMed ID: 22059525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity.
    Salluh JIF; Bozza FA; Soares M; Verdeal JCR; Castro-Faria-Neto HC; Lapa E Silva JR; Bozza PT
    Chest; 2008 Nov; 134(5):947-954. PubMed ID: 18753464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
    Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
    Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia.
    Rello J; Rodriguez A; Lisboa T; Gallego M; Lujan M; Wunderink R
    Crit Care Med; 2009 Feb; 37(2):456-62. PubMed ID: 19114916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admission.
    Salluh JIF; Rabello LSCF; Rosolem MM; Soares M; Bozza FA; Verdeal JCR; Mello GW; Castro Faria Neto HC; Lapa E Silva JR; Bozza PT
    J Crit Care; 2011 Oct; 26(5):496-501. PubMed ID: 21454038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
    Menéndez R; Martínez R; Reyes S; Mensa J; Filella X; Marcos MA; Martínez A; Esquinas C; Ramirez P; Torres A
    Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of procalcitonin in community-acquired pneumonia.
    Schuetz P; Suter-Widmer I; Chaudri A; Christ-Crain M; Zimmerli W; Mueller B;
    Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia.
    Chang PY; Tsao SM; Chang JH; Chien MH; Hung WY; Huang YW; Yang SF
    Clin Chim Acta; 2016 Dec; 463():174-180. PubMed ID: 27983998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia.
    Ramírez P; Ferrer M; Martí V; Reyes S; Martínez R; Menéndez R; Ewig S; Torres A
    Crit Care Med; 2011 Oct; 39(10):2211-7. PubMed ID: 21705887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia.
    Buising KL; Thursky KA; Black JF; MacGregor L; Street AC; Kennedy MP; Brown GV
    Thorax; 2006 May; 61(5):419-24. PubMed ID: 16449258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study.
    Ito A; Ito I; Inoue D; Marumo S; Ueda T; Nakagawa H; Taki M; Nakagawa A; Tatsumi S; Nishimura T; Shiota T; Ishida T
    Int J Infect Dis; 2020 Mar; 92():228-233. PubMed ID: 31981766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores.
    Valencia M; Badia JR; Cavalcanti M; Ferrer M; Agustí C; Angrill J; García E; Mensa J; Niederman MS; Torres A
    Chest; 2007 Aug; 132(2):515-22. PubMed ID: 17505026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
    Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
    Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study.
    Arnold FW; Wiemken TL; Peyrani P; Ramirez JA; Brock GN;
    Respir Med; 2013 Jul; 107(7):1101-11. PubMed ID: 23660396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.